Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro
Clear cell renal cell carcinoma (ccRCC) is the most aggressive urologic tumor, and its incidence and diagonosis have been continuously increasing. Identifying novel molecular biomarker for inhibiting the progression of ccRCC will facilitate developing new treatment strategies. Although methyltransfe...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.634542/full |
id |
doaj-99aacbb1bc6c4101a6acfcfa7f0132b8 |
---|---|
record_format |
Article |
spelling |
doaj-99aacbb1bc6c4101a6acfcfa7f0132b82021-02-26T06:53:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011110.3389/fonc.2021.634542634542Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In VitroWei Li0Shi Xu1Naixiong Peng2Zejian Zhang3Hua He4Ruoyu Chen5Dong Chen6Jiqing Fan7Xisheng Wang8Department of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Proctology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaDepartment of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, ChinaClear cell renal cell carcinoma (ccRCC) is the most aggressive urologic tumor, and its incidence and diagonosis have been continuously increasing. Identifying novel molecular biomarker for inhibiting the progression of ccRCC will facilitate developing new treatment strategies. Although methyltransferase-like 7B (METTL7B) was identified as a Golgi-associated methyltransferase, the function and mechanism of METTL7B in ccRCC development and progression has not been explored. METTL7B expression were significantly upregulated in ccRCC tissues (n = 60), which significantly associated with TNM classification, tumor size, lymph node metastasis, and poor prognosis for ccRCC patients. Functional studies showed downregulation of METTL7B inhibited cell proliferation, migration in vitro, and xenograft tumor formation in vivo. In addition, METTL7B knockdown promoted cell cycle arrest at G0/G1phase and induced cellular apoptosis. Taken together, downregulation of METTL7B inhibits ccRCC cell proliferation and tumorigenesis in vivo and in vitro. These findings provide a rationale for using METTL7B as a potential therapeutic target in ccRCC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.634542/fullMETTL7BmethyltransferaseccRCCproliferationtumorigenesis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei Li Shi Xu Naixiong Peng Zejian Zhang Hua He Ruoyu Chen Dong Chen Jiqing Fan Xisheng Wang |
spellingShingle |
Wei Li Shi Xu Naixiong Peng Zejian Zhang Hua He Ruoyu Chen Dong Chen Jiqing Fan Xisheng Wang Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro Frontiers in Oncology METTL7B methyltransferase ccRCC proliferation tumorigenesis |
author_facet |
Wei Li Shi Xu Naixiong Peng Zejian Zhang Hua He Ruoyu Chen Dong Chen Jiqing Fan Xisheng Wang |
author_sort |
Wei Li |
title |
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro |
title_short |
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro |
title_full |
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro |
title_fullStr |
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro |
title_full_unstemmed |
Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer Cells In Vivo and In Vitro |
title_sort |
downregulation of mettl7b inhibits proliferation of human clear cell renal cancer cells in vivo and in vitro |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-02-01 |
description |
Clear cell renal cell carcinoma (ccRCC) is the most aggressive urologic tumor, and its incidence and diagonosis have been continuously increasing. Identifying novel molecular biomarker for inhibiting the progression of ccRCC will facilitate developing new treatment strategies. Although methyltransferase-like 7B (METTL7B) was identified as a Golgi-associated methyltransferase, the function and mechanism of METTL7B in ccRCC development and progression has not been explored. METTL7B expression were significantly upregulated in ccRCC tissues (n = 60), which significantly associated with TNM classification, tumor size, lymph node metastasis, and poor prognosis for ccRCC patients. Functional studies showed downregulation of METTL7B inhibited cell proliferation, migration in vitro, and xenograft tumor formation in vivo. In addition, METTL7B knockdown promoted cell cycle arrest at G0/G1phase and induced cellular apoptosis. Taken together, downregulation of METTL7B inhibits ccRCC cell proliferation and tumorigenesis in vivo and in vitro. These findings provide a rationale for using METTL7B as a potential therapeutic target in ccRCC patients. |
topic |
METTL7B methyltransferase ccRCC proliferation tumorigenesis |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.634542/full |
work_keys_str_mv |
AT weili downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT shixu downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT naixiongpeng downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT zejianzhang downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT huahe downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT ruoyuchen downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT dongchen downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT jiqingfan downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro AT xishengwang downregulationofmettl7binhibitsproliferationofhumanclearcellrenalcancercellsinvivoandinvitro |
_version_ |
1724249841158062080 |